33-Breast metastatic trastuzumab three weekly

33-Breast metastatic trastuzumab three weekly trastuzumab CONCLUSION: Administering higher doses on a 3-weekly schedule did not compromise the efficacy and safety of trastuzumab in women with HER2-positive MBC, and trastuzumab Comment: Trastuzumab is a humanized IgG1κ monoclonal antibody targeting HER2 Annotated peptide sequences for this antibody are available from its IMGTmAb-DB

trastuzumab Trastuzumab deruxtecan may cause hair loss Any hair loss caused should be temporary and in most cases your hair will begin to grow back once your treatment has

trastuzumab In the DESTINY-Breast04 trial, trastuzumab deruxtecan showed superior activity over standard chemotherapy options in patients with HER2-low advanced breast Intravenous trastuzumab is effective as a single-agent, and in combination with chemotherapy it significantly improves the median time to disease